Table 2.

Inhibitory targets with FDA-approved HIV drugs through 2018.

Target	Viral/Host	Year Identified as Potential Target	Year of 1st Drug Approval in Class	Number of FDA-Approved Therapeutics (% of All Approved)†
Reverse transcriptase	Viral	1984	1987 NRTI	15 NRTI	6 multi-class combinations (11%)
			1996 NNRTI‡	8 NNRTI (42%)
gp120	Viral	1985		None§
Protease	Viral	1986	1995	13 (24%)	1 combination with RT (2%)
Tat:TAR/LTR	Viral	1986		None
gp41	Viral	1987	2003	1 (2%)
Capsid	Viral	1988		None
Integrase	Viral	1989	2007	4 (7%)	4 combinations with RT (7%)
RNase H	Viral	1989			None
CCR5	Host	1996	2007		1 (2%)
CD4¶	Host	1984	2018		1 (2%)
CXCR4	Host	1996			None
Other⁑	Host	Various	2014		1 (2%)

^†FDA-approved therapeutics for target as of 2018. Total = 55.

^‡NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = Non-nucleoside reverse transcriptase inhibitor.

^§FDA approved first drug in class in 2020, after the period examined by this analysis (see Appendix).

^¶Not a top 10 target.

^⁑Not top 10 targets. A full listing of all other targets is provided in the Appendix (Table A8). FDA-approved drug is a cytochrome P450 inhibitor.